Thomas Bieber

机构：DB Engineering & Consulting (Germany), CK-CARE, Ludwig-Maximilians-Universität München · ORCID：0000-0002-8800-3817

发表论文 880 篇 · 总被引 50307 次 · h-index 106

代表论文

• The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials (2024 · Nature Communications · 被引 38)
• Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy (2025 · Dermatology and Therapy · 被引 25)
• The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials (2024 · Journal of the American Academy of Dermatology · 被引 10)
• Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks (2025 · American Journal of Clinical Dermatology · 被引 7)
• Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy (2025 · Circulation Heart Failure · 被引 5)
• Langerhans Cell Modulation in Atopic Dermatitis Is TLR2 / SOCS1 ‐Dependent and JAK Inhibitor‐Sensitive (2025 · Allergy · 被引 4)